metsera glp-1 data slice reveals 7.5% weight loss at 36 days Metsera Seeks $289M Raise, $1.78B

Evaluation of changes in body composition and proinflammatory marker levels in ovariectomized rats with induced hyperthyroidism

Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial

Emerging evidence suggests that those patients living with insulin resistance or obesity may derive greater clinical benefit, highlighting the importance of a phenotype-based treatment approach

These contraindications are important screening criteria

Is BPC-157 or TB-500 better

Collectively, these findings support the use of GLP-1 RAs as a multifaceted therapeutic strategy in OSA management, offering concurrent benefits in sleep-disordered breathing, weight reduction, and blood pressure control